Table 1. Bevacizumab vs ranibizumab for PCV: patient demographics and comparisons at baseline.
| Bevacizumab (66 eyes of 63 patients)-treated group | Ranibizumab (60 eyes of 58 patients)-treated group | P | |
|---|---|---|---|
| Age (years; mean±SD) | 61.62±10.42 | 60.22±11.48 | 0.86a |
| Gender | 0.77b | ||
| Male | 46 (73.0%) | 40 (69.1%) | |
| Female | 17 (27.0%) | 18 (30.9%) | |
| BCVA (logMAR) | 0.91b | ||
| ≤0.3 | 17 (25.8%) | 12 (20.0%) | |
| >0.3∼≤0.7 | 29 (44.0%) | 31 (52.7%) | |
| >0.7 | 20 (30.2%) | 17 (27.3%) | |
| Mean initial GLD on ICGA (mean±SD), μm | 3213.5±1224.6 | 3421.8±1332.4 | 0.56a |
| PCV Classification16 | 0.64b | ||
| Exudative | 8 (12.1%) | 7 (11.7%) | |
| Hemorrhagic | 58 (87.9%) | 53 (88.3%) | |
| Location of lesions | 0.73b | ||
| Macular | 59 (89.4%) | 52 (86.6%) | |
| Peripapillary | 6 (9.1%) | 7 (11.7%) | |
| Peripheral | 1 (1.5%) | 1 (1.7%) |
Abbreviations: BCVA, best-corrected visual acuity; GLD, greatest linear dimension; ICGA, indocyanine green angiography; logMAR, logarithm of the minimum angle of resolution; PCV, polypoidal choroidal vasculopathy.
a
On the basis of student t-test.
b
On the basis of χ2-test.